Pharmatech’s SBIR Grant finishes a successful first year, with an even brighter future

 
DENVER - Aug. 7, 2013 - PRLog -- Pharmatech Inc. wrapped up their first productive year of their Small Business Innovative Research (SBIR)/ National Cancer Institute grant R44CA144362: A Patient-Centered Approach to Enrolling Rare Cancer Patients in Clinical Trials, in July, 2013.

This last year, Pharmatech developed a bio specimen protocol to do general molecular screenings that speeds up the process in which patients are connected with research institutes. This remarkably exact process improves the chance that a patient can find a study matching their requirements; it also allows research institutes to extend this information to applicable patients. Since this process has never been used before, Pharmatech and the Institutional Review Board (IRB), an ethics committee, want to insure that all protocols and contracts establish a high level of execution. Chief-Science-Officer, Matthew Wiener, reports that IRB approval is expected by the end of the week.

A (Just-In-Time) JIT taskforce is another of Pharmatech’s accomplishments. This program had been in development since 2005, and SBIR gave Pharmatech the chance to introduce JIT and other innovative ideas to a wide array of research institutes across the country. 25 highly productive and responsible research institutes are part of the taskforce, working specifically with JIT and SBIR to implement patient enrollment and execute clinical studies. Many institutes throughout the country focus on this as well. However, it usually takes one month to a year to get a project going, compared to JIT’s ten days. This year, Weill Cornell Medical College joined the task force, making it the first educational institution to take advantage of this efficient design.

Pharmatech has released a beta version of TrialPlus, a web-based access point for sites and sponsor to manage clinical trials more efficiently. The development of this intuitive program will streamline and connect the research projects with the patients and allow investigators to access a wide-range of clinical trials that are available to their study center. 

The commencement of the year two portion of the SBIR grant exemplifies a great success, in which Pharmatech invites all of its sponsors and sites to partake.  

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.

For more information about Pharmatech, please visit www.pharmatech.com.

The project described is supported by Award Number R44CA144362 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.
End
Source: » Follow
Email:***@pharmatech.com Email Verified
Tags:Cancer, Oncology, Cro, Smo, Sbir
Industry:Research, Medical
Location:Denver - Colorado - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Pharmatech Inc. PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share